

Special Issue

COVID-19 Vaccines: The Way Back to Normal Life Is Now Marked

Message from the Guest Editors

The SARS-CoV-2 virus has dramatically changed our lives, representing a serious public health problem with substantial morbidity and mortality and resulting in considerable economic damage worldwide. Despite nationwide lockdowns trying to control the widespread diffusion of the virus, more than 2.5 million infected individuals have died from COVID-19 over the last year. There are very few therapeutic options to date, and COVID-19 vaccine development has been accelerated in hope of rapidly containing the pandemic and returning to 'normal life'. Several vaccines have already been commercialized and are distributed in nationwide mass immunization campaigns. The aim of this Special Issue is to summarize general knowledge of COVID-19 vaccine responses in general and special populations (e.g., pediatric population, adolescents and pregnant women) and to discuss current knowledge, current recommendations and controversies regarding COVID-19 vaccination

Guest Editors

Prof. Dr. Matteo Bassetti

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

Dr. Antonio Vena

1. Department of Health Sciences, University of Genoa, 16126 Genoa, Italy
2. Clinica Malattie Infettive, Ospedale Policlinico San Martino-IRCCS, 16132 Genoa, Italy

Deadline for manuscript submissions

closed (22 July 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/98793

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).